Hormonal
Macrophage-secreted factors induce a profibrotic phenotype in human preadipocytes, characterized by increased proliferation, migration, and synthesis of extracellular matrix (ECM) proteins like fibronectin and collagen I.
Chronic obesity creates an inflammatory environment in fat tissue where immune cells signal fat precursor cells to become fibrotic and proliferative. This biological change makes fat tissue more resistant to change. Addressing obesity may require strategies that reduce inflammation, not just caloric restriction.
We show here that proinflammatory microenvironments are capable of inducing a considerable synthesis of several ECM proteins by human preadipocytes and are associated with their increased proliferation and migration.
Why this rating
Strong in vitro mechanistic evidence with human primary cells and supporting in vivo immunostaining data from obese individuals.
Source
Macrophage-Secreted Factors Promote a Profibrotic Phenotype in Human Preadipocytes
Mayoura Kéophiphath et al. · Molecular Endocrinology · 2008
DOI 10.1210/me.2008-0183
More from this paper
- Inhibin A, secreted by macrophages or induced in preadipocytes, is a major profibrotic factor driving the synthesis of fibronectin and collagen I.Good
- The fibronectin/integrin alpha5 partnership is essential for the proliferation of inflammatory preadipocytes.Good
- NF-kappaB and Cyclin D1 are critical molecular links connecting inflammation, ECM remodeling, and preadipocyte proliferation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →